Mark A. Goldsmith - 18 Sep 2023 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President and Chief Executive Officer, Director
Signature
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith
Issuer symbol
RVMD
Transactions as of
18 Sep 2023
Net transactions value
-$252,175
Form type
4
Filing time
20 Sep 2023, 16:12:40 UTC
Previous filing
06 Sep 2023
Next filing
24 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Sale $252,175 -8,054 -2.3% $31.31 349,332 18 Sep 2023 Direct F1, F2, F3
holding RVMD Common Stock 35,424 18 Sep 2023 Trust F4
holding RVMD Common Stock 35,424 18 Sep 2023 Trust F5
holding RVMD Common Stock 327,547 18 Sep 2023 Trust F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes.
F2 This transaction was executed in multiple trades at prices ranging from $31.0915 to $31.3108. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 Includes 174,000 RSUs.
F4 Held by Jonathan Henry Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F5 Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F6 Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Remarks:

President and Chief Executive Officer